International Clinical Trial: A Single-Center, Randomized, Controlled, Open-Label Phase II Clinical Study Comparing the Efficacy and Safety of rhTPO Versus Trilaciclib for Secondary Prophylaxis of Chemotherapy-Induced Thrombocytopenia (CTIT) in Solid Tumors

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132980) titled 'A Single-Center, Randomized, Controlled, Open-Label Phase II Clinical Study Comparing the Efficacy and Safety of rhTPO Versus Trilaciclib for Secondary Prophylaxis of Chemotherapy-Induced Thrombocytopenia (CTIT) in Solid Tumors' on Sept. 20.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Affiliated hangzhou first people's hospital, zhejiang university school of medicine

Condition: Cancer therapy induced thrombocytopenia

Intervention: Experimental group:rhTPO plus trilaciclib

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-09-30

Target Sample Size...